Hot Features
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the ... Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0293 | -13.239945775 | 0.2213 | 0.2279 | 0.18254 | 2668272 | 0.20418065 | CS |
| 4 | -0.072 | -27.2727272727 | 0.264 | 0.2999 | 0.18254 | 3420483 | 0.23330976 | CS |
| 12 | -0.0235 | -10.9048723898 | 0.2155 | 0.2999 | 0.18254 | 3254505 | 0.21565588 | CS |
| 26 | -0.0473 | -19.7659841204 | 0.2393 | 0.3389 | 0.18254 | 3066720 | 0.23743341 | CS |
| 52 | -0.083 | -30.1818181818 | 0.275 | 0.368 | 0.18254 | 3081747 | 0.24414409 | CS |
| 156 | -0.5555 | -74.3143812709 | 0.7475 | 1.11 | 0.16845 | 2613943 | 0.359552 | CS |
| 260 | -1.458 | -88.3636363636 | 1.65 | 2.05 | 0.16845 | 2434120 | 0.54726018 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.